Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion LUNG 2
NCT06151574Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of zongertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Progression-free survival. Started Feb 2024; status: active, not recruiting.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06151574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06151574.